New drug with short radiation and chemo for rectal cancer
Part of Cancer, Digestive system clinical trials.
This study tests a new drug (QL1706) combined with a short course of radiation and chemotherapy before surgery, for patients with MSS rectal cancer. It aims to see if this combination can shrink the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with rectal cancer that is locally advanced (has grown into nearby tissue or lymph nodes but hasn't spread to distant organs).
- The tumor is within 12 cm from the anal verge (the opening of the rectum).
- Your tumor is MSS or pMMR — a lab test result that shows it doesn't have certain DNA repair defects.
- You are in good general health (able to do daily activities) and your blood counts and organ function are within acceptable ranges.
- You have not had prior treatment for this cancer, such as radiation, chemo, or immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a short course of radiation with chemotherapy, targeted therapy, and immunotherapy before surgery for locally advanced rectal cancer. It aims to shrink the tumor and improve outcomes.
This trial tests a combination of short course radiation therapy, chemotherapy, and two immunotherapy drugs for people with a specific type of rectal cancer that is locally advanced but can still be removed by surgery. It may offer a more effective treatment option for those with mismatch repair proficient (pMMR) or microsatellite stable (MSS) tumors.
This trial tests combining immunotherapy with standard chemotherapy and radiation before surgery for locally advanced rectal cancer. It aims to see if this approach can improve outcomes for patients whose tumors have certain genetic features (pMMR or MSS).
This trial tests a new combination of short-course radiation, a targeted drug (fruquintinib), and an immunotherapy drug (PD-1 inhibitor) to treat rectal cancer before surgery. It aims to shrink the tumor and improve outcomes for patients with a specific type of rectal cancer.
This trial tests a short course of radiation therapy followed by a combination of three drugs (fruquintinib, adebrelimab, and CAPOX chemotherapy) before surgery for people with locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests whether combining short-course radiation with a chemotherapy regimen (CAPOX) and an immunotherapy drug (QL1706) can help treat rectal cancer that has spread to the liver. It is designed for patients who have not had any prior cancer treatment.
Hear when a new Locally Advanced Rectal Cancer (LARC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.